In Study 331-14-213, treatment with REXULTI 2 and 3 mg/day showed statistically significant improvement compared with placebo for the primary efficacy endpoint, the mean change in CMAI Total Score ...

The recommended target dose is 2 mg once daily, and can be increased to the maximum recommended daily dosage of 3 mg once daily after at least 14 days, based on clinical response and tolerability.

By week 10, the CAPS-5 total score was -17.4 in the sertraline-placebo group, -16.5 in the 2 mg brexpiprazole-sertraline group, and -18.3 in the 3 mg brexpiprazole-sertraline group.

The prospect of Lundbeck and Otsuka’s Rexulti becoming part of a new treatment for post-traumatic stress disorder (PTSD) appears more unlikely after a Friday meeting of experts in the field.